Siponimod is a medicine used to treat multiple sclerosis (MS). It's taken as a pill once a day. It works by keeping some immune cells in the lymph nodes so they can't reach and damage the brain and spinal cord.
Every report comes from a Lived member, sent anonymously.
Have you tried Mayzent (Siponimod) for MS (Multiple Sclerosis)?
Siponimod, sold under the brand name Mayzent, is a prescription tablet for adults with relapsing forms of multiple sclerosis (MS). In MS, the immune system attacks myelin, the protective coating around nerve cells in the brain and spinal cord, which slows or blocks nerve signals and leads to symptoms such as weakness, numbness, vision problems and trouble with balance. Siponimod is approved for three relapsing forms: clinically isolated syndrome (a first episode of MS-like symptoms lasting at least 24 hours), relapsing-remitting MS (flare-ups followed by periods of recovery) and active secondary progressive MS (a later stage in which disability steadily worsens while relapses or new inflammation still occur). Siponimod is a disease-modifying therapy. Its purpose is to reduce relapses and slow the buildup of disability, not to relieve day-to-day symptoms. Its main study was in people with secondary progressive MS. There, it lowered the chance that disability would measurably worsen compared with a placebo, and the benefit was clear in people whose disease was still active. In people with secondary progressive MS and no recent relapses, the study did not show a clear benefit. It is not approved for children or for primary progressive MS, the form that worsens steadily from the start.
Siponimod belongs to a group of medicines called sphingosine 1-phosphate (S1P) receptor modulators. It attaches to S1P receptors on lymphocytes, a type of white blood cell, and blocks their ability to leave the lymph nodes. Fewer of them circulate as a result: lymphocyte counts in the blood fall to roughly 20% to 30% of their usual level. In MS, lymphocytes that travel into the brain and spinal cord are thought to drive the inflammation that damages myelin. Holding more of them in the lymph nodes probably means fewer reach the nervous system, although researchers have not fully worked out how siponimod produces its benefit. The effect is reversible. Siponimod leaves the body within about 10 days of the last dose, and blood counts return to normal in most people in that time, though some effect on the immune system can last 3 to 4 weeks.
Siponimod is a tablet taken by mouth once a day. Before the first dose, the prescriber arranges several checks: a genetic test for CYP2C9 (explained below), an electrocardiogram (ECG, a tracing of the heart's electrical rhythm), recent blood counts and liver tests, an eye exam, a skin check, and a test for immunity to chickenpox. CYP2C9 is a liver enzyme that breaks siponimod down. People who carry two copies of a slow-working version (found in about 1 in 200 white people and 1 in 100 Asian people, per the label) cannot take siponimod because it builds up to high levels. People with one copy of that slow version take a lower maintenance dose of 1 mg a day instead of the usual 2 mg. Treatment begins with a starter pack that raises the dose gradually over four or five days, because the first doses temporarily slow the heart. People with certain heart conditions, such as a resting heart rate below 55 beats per minute, some types of heart block or a past heart attack or heart failure, take the first dose where staff can watch their pulse and blood pressure for at least six hours. Tablets are swallowed whole, not split, crushed or chewed. Missed doses matter more than with most daily pills. Missing a dose for more than 24 hours during the starter days, or missing four or more daily doses in a row later on, means restarting the starter pack from day 1 (with first-dose monitoring again for those who needed it). Call the prescriber before resuming after a gap.
The most common side effects in the main study were headache, higher blood pressure and raised liver enzymes on blood tests. Swelling in the legs or ankles, nausea, dizziness, diarrhea and pain in the arms or legs were also more frequent than with placebo. During the first week the heart rate usually drops a few beats per minute; most people feel nothing, and the few who notice dizziness or tiredness generally find it settles within a day. Fainting, chest discomfort or a very slow or irregular heartbeat during the starter days should be reported to the care team promptly. Because siponimod lowers circulating white blood cells, infections are more likely. Shingles (a painful rash from reactivated chickenpox virus) was more common, and rare serious or fatal infections have occurred, including cryptococcal meningitis, a fungal infection of the lining of the brain. Fever or other signs of infection should be reported to the care team. A rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) has also occurred, mostly after 18 months or more of treatment. Weakness on one side of the body or clumsiness that worsens over days to weeks, vision disturbances, or new confusion or memory problems need prompt contact with the prescriber. Macular edema, swelling of the retina at the back of the eye, can develop, most often in the first four months and more often in people with diabetes or a history of uveitis (inflammation inside the eye). Any blurry or changed vision should be reported, because swelling that lasts for months can cause permanent vision loss. Liver problems can show up as unexplained nausea, vomiting, belly pain, tiredness, yellowing of the skin or eyes, or dark urine, and these should be reported. Siponimod raises the risk of basal cell and squamous cell skin cancers, and melanoma has been reported, so new or changing skin spots should be checked. It can also slightly reduce lung function, so new or worsening shortness of breath is worth reporting. A sudden severe headache, confusion, vision disturbances or a seizure should be reported to the prescriber immediately. These can signal a rare brain swelling condition reported with similar medicines, where delayed treatment can cause lasting harm.
Siponimod is not used by people who, in the past six months, had a heart attack, stroke, mini-stroke (transient ischemic attack), unstable angina (chest pain that comes on at rest or is getting worse) or heart failure needing hospital care, or who have severe heart failure. Older events, such as a heart attack more than six months ago, do not rule it out but call for a monitored first dose. It is also not used with certain heart rhythm problems, such as advanced heart block or sick sinus syndrome (problems with the heart's built-in pacemaker or its electrical signal), unless a pacemaker is in place. Other heart and blood vessel conditions, uncontrolled high blood pressure and severe untreated sleep apnea generally call for a cardiologist's advice before starting. Medicines that slow the heart rate add to siponimod's effect during the starter days. These include beta-blockers (a common class of heart and blood pressure medicines), the blood pressure medicines verapamil and diltiazem, digoxin (a heart medicine), ivabradine (a heart failure medicine sold as Corlanor) and some drugs that control heart rhythm. The prescriber may change or briefly pause them before starting. Some medicines change siponimod levels: fluconazole, an antifungal, can raise them, while rifampin, an antibiotic used for tuberculosis, can lower them enough to make treatment less effective. Using siponimod alongside other immune-suppressing treatments, including steroids, or switching from an MS medicine whose effects last a long time, needs careful planning. Live vaccines (vaccines made from weakened live germs) should be avoided during treatment and for 4 weeks after stopping. People without confirmed chickenpox immunity are usually vaccinated and then wait at least a month before starting. Other vaccines may work less well while taking siponimod. Based on animal studies, siponimod may harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 10 days after the last dose, and should tell the prescriber right away about a pregnancy or plans for one. There is no information on whether siponimod passes into human breast milk.
The first week is the most closely managed part of treatment, because of the starter pack and the effect on heart rate. After that, siponimod is a single daily tablet. It is a long-term preventive treatment: it does not repair damage already done, and its benefit shows up over months to years as fewer relapses and slower progression rather than as something a person feels day to day. In the main study, relapses were about half as frequent as with placebo, although relapses were already uncommon in that group, and the effect on disability was more modest. Ongoing care includes blood pressure checks, eye exams during treatment and whenever vision changes, regular skin checks, and blood tests and MRI (magnetic resonance imaging) scans as the care team recommends. MRI can also pick up early signs of PML. Protective clothing and a sunscreen with high sun protection help lower skin cancer risk, and ultraviolet light therapy for skin conditions is not recommended during treatment. Do not stop siponimod without talking to the prescriber. Severe worsening of MS has rarely occurred after stopping medicines of this type, so new or worsening MS symptoms after stopping should be reported. Because its immune effects linger for weeks after the last dose, as described above, timing a switch to another treatment needs planning.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Mayzent (Siponimod), what you've noticed, or ask the community a question.